Phase 3 Study of Prostvac in Castration-resistant Prostate Cancer Discontinued

Phase 3 Study of Prostvac in Castration-resistant Prostate Cancer Discontinued
An independent Data Monitoring Committee (DMC) recommended that the Phase 3 PROSPECT study of Prostvac in men with metastatic castration-resistant prostate cancer (mCRPC) should be discontinued due to inadequate results. Prostvac is produced by Bavarian Nordic. In a press release sent out from the pharmaceutical company on Sept. 14, Bavarian Nordic’s president and CEO Paul Chaplin

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *